Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,270 | 183,363 | 178,902 | -45,191 | -25,210 |
| Depreciation Amortization | 596 | 2,402 | 1,800 | 1,307 | 656 |
| Income taxes - deferred | 1,077 | -185,495 | -185,843 | N/A | N/A |
| Accounts receivable | 5,236 | -8,675 | -7,174 | -3,823 | -25,455 |
| Accounts payable and accrued liabilities | -6,508 | 6,031 | -399 | 654 | 1,515 |
| Other Working Capital | 260 | -22,575 | 1,379 | -15,248 | -19,222 |
| Other Operating Activity | 7,342 | 30,756 | 28,718 | 17,631 | 30,870 |
| Operating Cash Flow | $-4,267 | $5,807 | $17,383 | $-44,670 | $-36,846 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -37,896 | -8,064 | 34,638 | 15,566 | -22,723 |
| PPE Investments | -24 | -14 | -56 | -24 | N/A |
| Investing Cash Flow | $-37,920 | $-8,078 | $34,582 | $15,542 | $-22,723 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 510 | 3,417 | 2,127 | 1,558 | 992 |
| Other Financing Activity | -420 | -901 | -801 | -593 | -569 |
| Financing Cash Flow | $90 | $2,516 | $1,326 | $965 | $423 |
| Beginning Cash Position | 122,715 | 122,470 | 122,470 | 122,470 | 122,470 |
| End Cash Position | 80,618 | 122,715 | 175,761 | 94,307 | 63,324 |
| Net Cash Flow | $-42,097 | $245 | $53,291 | $-28,163 | $-59,146 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,267 | 5,807 | 17,383 | -44,670 | -36,846 |
| Capital Expenditure | -24 | -105 | -137 | -115 | N/A |
| Free Cash Flow | -4,291 | 5,702 | 17,246 | -44,785 | -36,846 |